RT Journal Article
T1 L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution.
A1 Nguyen, Thu H M
A1 Carreira, Patricia E
A1 Sanchez-Luque, Francisco J
A1 Schauer, Stephanie N
A1 Fagg, Allister C
A1 Richardson, Sandra R
A1 Davies, Claire M
A1 Jesuadian, J Samuel
A1 Kempen, Marie-Jeanne H C
A1 Troskie, Robin-Lee
A1 James, Cini
A1 Beaven, Elizabeth A
A1 Wallis, Tristan P
A1 Coward, Jermaine I G
A1 Chetty, Naven P
A1 Crandon, Alexander J
A1 Venter, Deon J
A1 Armes, Jane E
A1 Perrin, Lewis C
A1 Hooper, John D
A1 Ewing, Adam D
A1 Upton, Kyle R
A1 Faulkner, Geoffrey J
K1 L1
K1 LINE-1
K1 chemoresistance
K1 ovarian cancer
K1 retrotransposon
AB LINE-1 (L1) retrotransposons are a source of insertional mutagenesis in tumor cells. However, the clinical significance of L1 mobilization during tumorigenesis remains unclear. Here, we applied retrotransposon capture sequencing (RC-seq) to multiple single-cell clones isolated from five ovarian cancer cell lines and HeLa cells and detected endogenous L1 retrotransposition in vitro. We then applied RC-seq to ovarian tumor and matched blood samples from 19 patients and identified 88 tumor-specific L1 insertions. In one tumor, an intronic de novo L1 insertion supplied a novel cis-enhancer to the putative chemoresistance gene STC1. Notably, the tumor subclone carrying the STC1 L1 mutation increased in prevalence after chemotherapy, further increasing STC1 expression. We also identified hypomethylated donor L1s responsible for new L1 insertions in tumors and cultivated cancer cells. These congruent in vitro and in vivo results highlight L1 insertional mutagenesis as a common component of ovarian tumorigenesis and cancer genome heterogeneity.
YR 2018
FD 2018
LK http://hdl.handle.net/10668/12650
UL http://hdl.handle.net/10668/12650
LA en
DS RISalud
RD Apr 7, 2025